
Roche to Acquire 89bio and Its Phase 3 FGF21 Analog for Moderate to Severe MASH
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH 89bio’s pegozafermin allows for a potentially…












